Landmark achievements for Greater Manchester skin research team
A Greater Manchester skin research team has been praised following a series of landmark achievements.
The Dermatopharmacology Unit is part of the School of Biological Sciences at The University of Manchester. The team is based in the Greater Manchester Dermatology Centre at Salford Royal NHS Foundation Trust.
Over the past year they have achieved a string of “firsts” for which they were congratulated by the pharmaceutical companies sponsoring the trials.
The team achieved:
- The first UK patient visit (second in Europe) for OASIS-2 - A multicentre, randomised, double-blind, placebo-controlled study comparing the efficacy and safety of Mirikizumab to Secukinumab and placebo in patients with moderate-to-severe plaque psoriasis. The team also exceeded its original target of five patients.
- The first UK recruit to STELLAR TEENS - An observational, post-authorisation safety study of Ustekinumab in the treatment of paediatric patients aged 12 years and older with moderate to severe plaque psoriasis.
- The first UK site to screen a patient for M16 766 - Risankizumab versus Secukinumab for subjects with moderate to severe plaque psoriasis.
- The first site in Europe to recruit to PSoHO - Psoriasis Study of Health Outcomes (PSoHO), an international, observational study of three-year health outcomes in the biologic treatment of moderate-to-severe plaque psoriasis.
- The first site in the UK to randomise a patient to PS0015 (BE RADIANT) - A multicentre, randomised, double-blind, secukinumab-controlled, parallel-group study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis.
Annabelle Smyth, Clinical Development Consultant with Eli Lilly and Company Ltd which sponsored OASIS-2, said: “Working with the team throughout the study set-up phase was a real pleasure and we are so appreciative of the level of motivation and commitment we have seen. We had an ambitious site set-up plan and the team rose to the challenge and delivered.
“This is truly a great performance and demonstration of the competitive metrics the UK can achieve when all parties are on board and working together with a ‘can do’ attitude.”
Clinical Research Network (CRN) Greater Manchester supports the delivery of studies locally on the National Institute for Health Research (NIHR) portfolio.
Mary Speake, CRN Greater Manchester Dermatology Specialty Management Lead, said: “The team has worked superbly well to ensure that studies have been set-up efficiently, meaning that local patients with these conditions have the opportunity to take part in research at the earliest convenience.”
